Rechovot
RECHOVOT, Israel, December 7 -
- 60 people, males and females, aged 18-49, participated in the trial
- The antibodies generated by the vaccine specifically identified several
strains of influenza, including the swine flu strain
- BiondVax's CEO Dr.